Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

This study is looking for men and women who are newly diagnosed with multiple myeloma. You need to be between 18 and 65 years old. Your multiple myeloma must meet certain criteria, which your doctor will be able to explain, and it needs to be the kind that can be measured.

You also need to be well enough to take part. This means your general health and fitness, measured by something called a 'performance status' score, must be at a certain level. Your blood and other lab test results should also be within a specific range.

If you are a woman who could become pregnant, you'll need to have negative pregnancy tests and use two reliable forms of contraception. Men also have specific requirements about contraception. It's important to discuss all these details with your doctor to see if this study could be right for you.

If you join this study, you will first receive a standard course of treatment called D-VRd. After this, tests will be done to check for any remaining cancer cells (minimal residual disease). Depending on these results, you will then receive one of the new drug combinations (either teclistamab with lenalidomide, or teclistamab with talquetamab).

Participation usually involves regular visits to the clinic for medical check-ups, blood tests, and to receive your study medications. The frequency and length of these visits will depend on the specific treatment phase you are in. You will be closely monitored throughout the study for any side effects and to see how well the treatment is working. After the main treatment period, there will be follow-up appointments to track your health over time. The total duration of your participation will be fully explained by the study team.